SpyGlass Pharma IPO: offering terms from its S-1
SpyGlass Pharma priced its IPO at $16 a share on 6 Feb 2026 and raised $150 million. Its shares trade on Nasdaq as SGP.
Headlines
- Net loss, 2024
- $29M
- IPO price
- $16
- $150M raised
SpyGlass Pharma IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- SGP
- IPO price
- $16
- Shares offered
- 9,375,000
- Raised
- $150M
- Registered
- $183M, the amount the filing fee is paid on
- Underwriters
- Jefferies, Leerink Partners, Citigroup and Stifel
- First filed
- 16 Jan 2026
SpyGlass Pharma revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | - | -$27M | -$29M |
| First nine months of 2025 | - | -$28M | -$27M |
SpyGlass Pharma share structure and company facts
- Employees
- 65
- Headquarters
- Aliso Viejo, California
SpyGlass Pharma shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $16
- Priced 6 Feb 2026
- First close
- $26.40
- +65% on the IPO price
- Latest close
- $29.91
- +87% on the IPO price
SpyGlass Pharma's IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from SpyGlass Pharma's newest prospectus (424B4 filed 6 Feb 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.